Palbociclib Resistant Stable T47D Cell Line
| Catalog Number |
CBCL-594 |
| Price |
Online Inquiry |
| Unit Quantity |
1x106 cells / 1.0 ml |
Introduction
Stable T47D cell clone resistant to CDK4/6 inhibitors
Application
Drug screening and biological assays
Background
Palbociclib, branded as Ibrance, is a selective inhibitor of cyclin-dependent inhibitor of CDK4 and CDK6, and was approved for treatment of HR-positive and HER2 negative breast cancer.
Product Information
| Category |
Immune Molecules Cell Lines |
| Cell Line Name |
Palbociclib Resistant Stable T47D Cell Line |
| Pharmaceutical Target |
Immune Molecules |
| Species |
Human |
| Host Cell Line |
T47D |
| Cell Type |
Mammary gland epithelial cells |
| Morphology |
Epithelial |
| Growth Properties |
Adherent |
| Seeding Density |
Thaw entire contents into an appropriate T25 flask. |
| Subculture Ratio |
Recommended a ratio of 1:3-1:5. |
| Recommended Medium |
RPMI1640 + 10% FBS + 0.2 U/ml insulin + 5 μM Palbociclib |
| Storage Method |
Frozen in liquid nitrogen with 70% medium, 20% FBS and 10% DMSO |
| Stability |
Stable in culture over 10 passages |
| QC |
WB |
| Shipping |
Shipping in dry ice |
| Biosafety Level |
BSL-1 |
| Caution |
For Research Use Only |
For research use only. Not for any other purpose.
